Geron Corp (GERN)

$1.27 +0.01 (0.79%)
Market Cap 802.52M
Revenue (ttm) 76.99M
Net Income (ttm) -174.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.74%
Debt to Equity Ratio 0.44
Volume 8,008,200
Avg Vol 10,982,522
Day's Range N/A - N/A
Shares Out 636.92M
Stochastic %K 5%
Beta 0.64
Analysts Sell
Price Target $3.39

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 473 7700
Address:
919 East Hillsdale Boulevard, Suite 250, Foster City, United States
meistermell
meistermell Jul. 17 at 5:06 AM
$GERN This is arguably one of the best entry points. Even with cotninued modest expansion they have enough cash to cruise to profitability, and success in MDS would be a huge expansion of TAM.
0 · Reply
eunkyo
eunkyo Jul. 16 at 9:44 PM
$GERN GERN – Bull vs. Bear (No RS Since IPO, I Hear?!) Alright investors, let's talk GERN. This company has a wild history: as far as I know, they've had NO reverse stock split (RS) since going public! But their new drug is just 1 year commercialized & the stock has CRATERED. 📉 Doctors are cautious with new drugs, demanding data. Sales are low vs. rivals, but for a newly commercialized drug, meaningful progress is clear. EU entry is confirmed, with sales coming soon. Plus, combo therapy trials with competitors could lead to first-line use in a few years! More Phase 3 trials are ongoing for other diseases. While trials are tough, optimism is high for commercialized meds. My Take: Optimistic: This could be the best entry point for years. Pessimistic: Expect market/clinical flops. Wildcard: No RS since IPO, but a new CEO could change that. Nothing's certain. Trust your gut.
1 · Reply
Mail_Dog
Mail_Dog Jul. 16 at 4:51 PM
$GERN Imo, SHs are getting the shaft here but perhaps future good news is awaiting, but not getting that feeling right now..
0 · Reply
dgreenway
dgreenway Jul. 16 at 4:27 PM
$GERN Please sell this fucking company……..
0 · Reply
ZoeyTanner
ZoeyTanner Jul. 16 at 2:08 PM
$GERN Back down she will go. It is very apparent to those that hold that ceo (interim or not) cares less about shareholders and the pps than previous administrations. Ms. Bir is figuring out how to squeeze by with reverse stock split and get all warrants, perks and incentives for the insider chosen ones.
0 · Reply
Tambaki
Tambaki Jul. 16 at 1:39 PM
$GERN anyone know at what point this gets delisted?
1 · Reply
Fern64
Fern64 Jul. 15 at 10:41 PM
$GERN https://www.hmpgloballearningnetwork.com/site/onc/conference-coverage/imetelstat-combined-ruxolitinib-demonstrates-promising-activity
2 · Reply
afc2881
afc2881 Jul. 15 at 8:11 PM
$GERN Wtf is going on at corporate hdqtrs. Is anybody there?? Is anybody listening?? Anything would be nice to hear to let us know u r still "There." Over 400m in cash & we r at $1.26. Totally unacceptable. I'm sorry I ever invested in this pos.
3 · Reply
ZoeyTanner
ZoeyTanner Jul. 15 at 7:57 PM
$GERN Extremely bullish, eh? Not Geron..sorry the Ai here has flipped his cone head. This basically has gone straight down for over a year. With absolutely no geron team to support shareholders, you are on your own. Dam, 52 week lows.. hanks Goldman
0 · Reply
Percy619
Percy619 Jul. 15 at 7:25 PM
$GERN basically straight down from $4.71, needs a little catalyst, should bounce back.
0 · Reply
Latest News on GERN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 18, 2025, 4:10 PM EDT - 4 weeks ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Conservative Vision Of A Positive Future For Geron

Jun 3, 2025, 9:57 AM EDT - 6 weeks ago

Conservative Vision Of A Positive Future For Geron

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 28, 2025, 8:30 AM EDT - 7 weeks ago

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

May 9, 2025, 8:28 AM EDT - 2 months ago

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

May 8, 2025, 11:24 PM EDT - 2 months ago

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:50 PM EDT - 2 months ago

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

May 7, 2025, 12:33 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 2 months ago

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 24, 2025, 9:33 PM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 18, 2025, 4:30 PM EDT - 3 months ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 9, 2025, 10:40 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Mar 31, 2025, 4:32 PM EDT - 3 months ago

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 4:30 PM EDT - 3 months ago

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 3 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS LLY NVO SEPN

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

Mar 22, 2025, 12:31 PM EDT - 4 months ago

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

TBBK

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Mar 17, 2025, 5:19 PM EDT - 4 months ago

Geron Corp: How Concerned Should We Be About Rytelo Sales?

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Mar 17, 2025, 7:42 AM EDT - 4 months ago

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)

Mar 14, 2025, 3:04 PM EDT - 4 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

Mar 11, 2025, 4:30 PM EDT - 4 months ago

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

Geron Corporation Announces Departure of Chief Executive Officer

Mar 11, 2025, 4:02 PM EDT - 4 months ago

Geron Corporation Announces Departure of Chief Executive Officer

meistermell
meistermell Jul. 17 at 5:06 AM
$GERN This is arguably one of the best entry points. Even with cotninued modest expansion they have enough cash to cruise to profitability, and success in MDS would be a huge expansion of TAM.
0 · Reply
eunkyo
eunkyo Jul. 16 at 9:44 PM
$GERN GERN – Bull vs. Bear (No RS Since IPO, I Hear?!) Alright investors, let's talk GERN. This company has a wild history: as far as I know, they've had NO reverse stock split (RS) since going public! But their new drug is just 1 year commercialized & the stock has CRATERED. 📉 Doctors are cautious with new drugs, demanding data. Sales are low vs. rivals, but for a newly commercialized drug, meaningful progress is clear. EU entry is confirmed, with sales coming soon. Plus, combo therapy trials with competitors could lead to first-line use in a few years! More Phase 3 trials are ongoing for other diseases. While trials are tough, optimism is high for commercialized meds. My Take: Optimistic: This could be the best entry point for years. Pessimistic: Expect market/clinical flops. Wildcard: No RS since IPO, but a new CEO could change that. Nothing's certain. Trust your gut.
1 · Reply
Mail_Dog
Mail_Dog Jul. 16 at 4:51 PM
$GERN Imo, SHs are getting the shaft here but perhaps future good news is awaiting, but not getting that feeling right now..
0 · Reply
dgreenway
dgreenway Jul. 16 at 4:27 PM
$GERN Please sell this fucking company……..
0 · Reply
ZoeyTanner
ZoeyTanner Jul. 16 at 2:08 PM
$GERN Back down she will go. It is very apparent to those that hold that ceo (interim or not) cares less about shareholders and the pps than previous administrations. Ms. Bir is figuring out how to squeeze by with reverse stock split and get all warrants, perks and incentives for the insider chosen ones.
0 · Reply
Tambaki
Tambaki Jul. 16 at 1:39 PM
$GERN anyone know at what point this gets delisted?
1 · Reply
Fern64
Fern64 Jul. 15 at 10:41 PM
$GERN https://www.hmpgloballearningnetwork.com/site/onc/conference-coverage/imetelstat-combined-ruxolitinib-demonstrates-promising-activity
2 · Reply
afc2881
afc2881 Jul. 15 at 8:11 PM
$GERN Wtf is going on at corporate hdqtrs. Is anybody there?? Is anybody listening?? Anything would be nice to hear to let us know u r still "There." Over 400m in cash & we r at $1.26. Totally unacceptable. I'm sorry I ever invested in this pos.
3 · Reply
ZoeyTanner
ZoeyTanner Jul. 15 at 7:57 PM
$GERN Extremely bullish, eh? Not Geron..sorry the Ai here has flipped his cone head. This basically has gone straight down for over a year. With absolutely no geron team to support shareholders, you are on your own. Dam, 52 week lows.. hanks Goldman
0 · Reply
Percy619
Percy619 Jul. 15 at 7:25 PM
$GERN basically straight down from $4.71, needs a little catalyst, should bounce back.
0 · Reply
TradeSlaughterPrevail
TradeSlaughterPrevail Jul. 15 at 6:44 PM
$GERN tentatively setting a buy order at $1.21 Let’s see if that cracks or holds in the coming weeks.
0 · Reply
sepsis74
sepsis74 Jul. 15 at 3:08 PM
$IOVA $RCKT $GERN Goldman has an awful lot of sell recommendations out on biotechs that have already gotten crushed. It's like they have a directive out. Hope they get burned badly by a rebound in the whole sector.
4 · Reply
Find_the_Cure
Find_the_Cure Jul. 15 at 11:57 AM
$GERN does anyone remember GERN’s previous CEO Thomas O’Karma and the human stem cell lines from invitro clinics that GERN was immortalizing??
0 · Reply
DAWGNuts
DAWGNuts Jul. 15 at 12:43 AM
$GERN Numerous studies in cell lines (e.g., pancreatic cancer, glioblastoma, myeloid leukemia) and animal models have consistently shown that imetelstat's inhibition of telomerase leads to telomere shortening, which in turn triggers a DNA damage response and subsequently induces either apoptosis (programmed cell death) or cellular senescence. These findings have been published in peer-reviewed journals for many years (some as far back as 2014, 2010, etc., based on the search results).
1 · Reply
Akwaba76
Akwaba76 Jul. 14 at 10:49 PM
$GERN last testimony I m gonna post.... But there are plenty, sometimes it works, sometimes it doesnt....but it's hard to believe this drug will not increase sales. So keep the spirit alive👊
5 · Reply
defman
defman Jul. 14 at 9:41 PM
$GERN
0 · Reply
Mail_Dog
Mail_Dog Jul. 14 at 7:28 PM
$GERN Imo, need a motivated management team that takes care of both business & SH needs - which has been severely lacking in this Co…
0 · Reply
precise
precise Jul. 14 at 7:23 PM
$GERN Just dump this toxic garbage
0 · Reply
ZoeyTanner
ZoeyTanner Jul. 14 at 3:13 PM
$GERN This is such a disappointment, no matter the 90%sentiment. Look what just a little imagination can do for small biotech SONN..thats how you care for shareholders. Around gern, the only good for shareholders is dilution, warrants, and incentives for insiders.
0 · Reply
Kazarius
Kazarius Jul. 14 at 3:14 AM
$GERN https://www.youtube.com/watch?v=A9FQ4T9zJJ8
2 · Reply
Akwaba76
Akwaba76 Jul. 13 at 6:06 AM
$GERN
4 · Reply